| 崔君,李海.多奈哌齐片联合丁苯酞软胶囊治疗血管性痴呆 49例[J].安徽医药,2021,25(2):408-412. |
| 多奈哌齐片联合丁苯酞软胶囊治疗血管性痴呆 49例 |
| Clinical observation of donepezil tablet and butylphthalide capsule in the treatment of vascular dementia:an analysis of 49 cases |
| |
| DOI：10.3969/j.issn.1009-6469.2021.02.048. |
| 中文关键词: 痴呆，血管性 多奈哌齐 丁苯酞软胶囊 疗效 |
| 英文关键词: Dementia, vascular Donepezil Butylphthalide soft capsule Curative effect |
| 基金项目: |
|
| 摘要点击次数: 1454 |
| 全文下载次数: 428 |
| 中文摘要: |
| 目的观察多奈哌齐片联合丁苯酞软胶囊治疗血管性痴呆(VD)的疗效。方法纳入中国人民解放军海军第九〇五医院 2015年 1月至 2018年 12月收治的 VD病人 98例，依照随机数字表法分为观察组(n = 49)、对照组(n = 49)，在对症治疗基础上，对照组给予多奈哌齐片治疗，观察组给予多奈哌齐片、丁苯酞软胶囊治疗。观察两组治疗前后日常生活能力量表(ADL)、简易精神状态量表(MMSE)、临床痴呆评定量表(CDR)评分，事件相关电位(ERP)P300，血清丙二醛(MDA)、超氧化物歧化酶(SOD)水平，血浆胰岛素样生长因子-1(IGF-1)、细胞间黏附分子-1(IGAM-1)、转化生长因子-β(TGF-β)水平，不良反应。结果治疗后，观察组 ADL［(85.19±8.73)分比(74.28±7.62)分］MMSE评分［(21.74±2.23)分比(19.26±2.04)分］均大于对照组， CDR评分小于对照［(0.82±0.09)分比(1.17±0.11)分，P < 0.05］。、观察组 P300波幅［(8.85±0.89)μV比(8.02±0.82)μV］大于对照组，P300潜伏期［(322.77±34.57)ms比(362.96±37.82)ms］小于对照组(P < 0.05)。观察组 SOD［(118.76±12.38)nU/mL比(97.96±11.82)nU/mL］、IGF-1［(15.38±1.64)ng/mL比(14.87±1.59)ng/mL］、ITGF-β［(30.22±3.21)ng/mL比(27.95±3.03)ng/mL］水平均高于对照组，MDA［(3.23±0.34)nmol/mL比(3.61±0.39)nmol/mL］、GAM-1［(221.65±24.39)ng/mL比(243.87±25.16)ng/mL］水平低于对照组(P < 0.05)。观察组总有效率(73.47%)高于对照组(51.02%)(P < 0.05)。两组均未见明显不良反应。结论 多奈哌齐片联合丁苯酞可有效抑制脑区自由基及炎性因子等有害物质生成，保护脑区神经细胞，促进脑区受损神经细胞修复，改善 VD病人认知功能，疗效显著，且较为安全，有助于 VD病人康复。 |
| 英文摘要: |
| Objective To study the efficacy of donepezil tablet and butylphthalide capsule on vascular dementia (VD).Methods A total of 98 VD patients admitted to The No.905 Navy Hospital of the ChinesePeople's LiberationArmyfrom January 2015 to December2018 were included and assigned into experimental group (n = 49) and control group (n = 49) according to the random number table method. Based on symptomatic treatment, the control group was treated with donepezil tablets, while the experimental group was treated withdonepezil tablets and butylphthalide soft capsules. Observation was made of two groups before and after treatment in scores of activity ofdaily living scale (ADL), mini-mental state examination (MMSE), and clinical dementia rating scale (CDR), event related potential (ERP)P300, levels of serum malondialdehyde (MDA), superoxide dismutase (SOD), plasma insulin-like growth factor-1 (IGF-1) and intercellular adhesion molecule-1 (IGAM-1), transforming growth factor-β (TGF-β), and adverse reactions.Results After treatment, ADL[(85.19± 8.73) vs. (74.28±7.62)] and MMSE[(21.74±2.23) vs. (19.26±2.04)] scores in the experimental group were higher than those in the controlgroup, and CDR scores were lower than those in the control group [(0.82±0.09) vs. (1.17±0.11)P < 0.05].The amplitude of P300 in the experimental group was larger than that in the control group[(8.85±0.89)μV vs. (8.02±0.82)μV], and the incubation period of P300 was smaller than that in the control group [(322.77±34.57)ms vs. (362.96±37.82)ms,P < 0.05]. SOD[(118.76±12.38)nU/mL vs. (97.96±11.82)nU/mL], IGF-1[(15.38±1.64)ng/mL vs. (14.87±1.59)ng/mL] and TGF-β[(30.22±3.21)ng/mL vs. (27.95±3.03)ng/mL] levels in the experimental group were all higher than those in the control group, while MDA[(3.23±0.34)nmol/mL vs. (3.61±0.39)nmol/mL] and GAM-1 levels [(221.65±24.39)ng/mL vs. (243.87±25.16)ng/mL] were lower than those in the control group (P < 0.05). The total effective rate of the experimental group was higher than that of the control group (73.47% vs. 51.02%; P < 0.05). No significant adverse reactions were found in the two groups.Conclusions Donepezil tablets combined with butylphthalide capsules can effectively inhibit the formation of free radicals,inflammatory factors and other harmful substances, protect the nerve cells, and promote the repair of damaged nerve cells in the brain region, and improve the cognitive function ofVD patients.The efficacy is significant and safe, which is conducive to the recovery ofpatients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
